Skip to main content
SpringerLink
Log in

Cefazolin: lower treatment failure risk than vancomycin for MSSA

  • Epidemiology clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Chan KE, Warren HS, Thadhani RI, Steele DJR, Hymes JL, Maddux FW, Hakim RM.Prevalence and Outcomes of Antimicrobial Treatment for Staphylococcus aureus Bacteremia in Outpatients with ESRD. Journal of the American Society of Nephrology 23: [18 pages], 16 Aug 2012. Available from: URL: http://dx.doi.org/10.1681/ASN.2012010050

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cefazolin: lower treatment failure risk than vancomycin for MSSA. React. Wkly. 1418, 5 (2012). https://doi.org/10.2165/00128415-201214180-00019

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214180-00019

Keywords

Search

Navigation